Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies

[1]  P. Marrack,et al.  Nedd4 augments the adaptive immune response by promoting ubiquitin-mediated degradation of Cbl-b in activated T cells , 2008, Nature Immunology.

[2]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Hirano,et al.  Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. , 2008, Immunity.

[4]  P. Muranski,et al.  Tumor-specific Th17-polarized cells eradicate large established melanoma. , 2008, Blood.

[5]  A. Corti,et al.  Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. , 2008, Trends in immunology.

[6]  Yuelei Shen,et al.  TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function , 2008, Nature.

[7]  M. Suresh,et al.  Effects of IL-7 on memory CD8 T cell homeostasis are influenced by the timing of therapy in mice. , 2008, The Journal of clinical investigation.

[8]  T. Mak,et al.  TNF-α is critical for antitumor but not antiviral T cell immunity in mice , 2007 .

[9]  T. Mak,et al.  The role of E3 ligases in autoimmunity and the regulation of autoreactive T cells. , 2007, Current opinion in immunology.

[10]  C. Liu,et al.  IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. , 2007, International immunology.

[11]  Josef M. Penninger,et al.  Spontaneous tumor rejection by cbl-b–deficient CD8+ T cells , 2007, The Journal of experimental medicine.

[12]  E. Jaffee,et al.  Cancer immunologists and cancer biologists: why we didn't talk then but need to now. , 2007, Cancer research.

[13]  R. Hodes,et al.  Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. , 2007, The Journal of clinical investigation.

[14]  F. Finkelman,et al.  Cutting Edge: Limiting Amounts of IL-7 Do Not Control Contraction of CD4+ T Cell Responses1 , 2007, The Journal of Immunology.

[15]  C. Loddenkemper,et al.  Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease , 2007, The Journal of experimental medicine.

[16]  C. Blank,et al.  Immune resistance orchestrated by the tumor microenvironment , 2006, Immunological reviews.

[17]  Y. Iwamoto,et al.  A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance , 2006, Nature Immunology.

[18]  L. Turka,et al.  TRAF6 is a T cell–intrinsic negative regulator required for the maintenance of immune homeostasis , 2006, Nature Medicine.

[19]  Ralph Weissleder,et al.  Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. , 2006, Immunity.

[20]  S. Rosenberg,et al.  IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells , 2006, Journal of immunotherapy.

[21]  Gefeng Zhu,et al.  B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma , 2006, The Journal of experimental medicine.

[22]  C. Dong,et al.  New battlefields for costimulation , 2006, The Journal of experimental medicine.

[23]  R. Flavell,et al.  Cutting Edge: Deficiency in the E3 Ubiquitin Ligase Cbl-b Results in a Multifunctional Defect in T Cell TGF-β Sensitivity In Vitro and In Vivo , 2006, The Journal of Immunology.

[24]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[25]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[26]  S. Rosenberg,et al.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells , 2005, The Journal of experimental medicine.

[27]  F. Sallusto,et al.  Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia , 2005, The Journal of experimental medicine.

[28]  T. Fry,et al.  Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. , 2005, The Journal of clinical investigation.

[29]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[30]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[31]  D. Moskophidis,et al.  TCR affinity and negative regulation limit autoimmunity , 2004, Nature Medicine.

[32]  A. Strasser,et al.  T-lymphocyte death during shutdown of an immune response. , 2004, Trends in immunology.

[33]  C. Elly,et al.  Itch E3 ligase-mediated regulation of TGF-beta signaling by modulating smad2 phosphorylation. , 2004, Molecular cell.

[34]  D. Mueller.  E3 ubiquitin ligases as T cell anergy factors , 2004, Nature Immunology.

[35]  M. Callahan,et al.  Resistance to CD4+CD25+ Regulatory T Cells and TGF-β in Cbl-b−/− Mice , 2004, The Journal of Immunology.

[36]  A. Strasser,et al.  Shutdown of an acute T cell immune response to viral infection is mediated by the proapoptotic Bcl-2 homology 3-only protein Bim , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[38]  Min Huang,et al.  IL-7 inhibits fibroblast TGF-β production and signaling in pulmonary fibrosis , 2002 .

[39]  T. Hunter,et al.  Dysregulation of T lymphocyte function in itchy mice: a role for Itch in TH2 differentiation , 2002, Nature Immunology.

[40]  T. Fry,et al.  Interleukin-7 restores immunity in athymic T-cell-depleted hosts. , 2001, Blood.

[41]  R. Derynck,et al.  Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Wrana,et al.  Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. , 2000, Molecular cell.

[43]  E. Shevach,et al.  Cbl-b regulates the CD28 dependence of T-cell activation , 2000, Nature.

[44]  H. Nishina,et al.  Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b , 2000, Nature.

[45]  R. Zinkernagel,et al.  Virus‐specific major MHC class II‐restricted TCR‐transgenic mice: effects on humoral and cellular immune responses after viral infection , 1998, European journal of immunology.

[46]  D. Hanahan,et al.  Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.

[47]  B. Dörken,et al.  Tumor cells cotransfected with interleukin‐7 and B7.1 genes induce CD25 and CD28 on tumor‐infiltrating T lymphocytes and are strong vaccines , 1995, European journal of immunology.

[48]  Robert E. Miller,et al.  Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo , 1994, The Journal of experimental medicine.

[49]  T. Honjo,et al.  Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[50]  H. Pircher,et al.  Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice , 1991, Cell.

[51]  H. Pircher,et al.  Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen , 1989, Nature.

[52]  P. Scherle,et al.  Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors , 2006, Nature Reviews Cancer.

[53]  L. Butterfield,et al.  Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. , 2000, Human gene therapy.

[54]  D. Hanahan,et al.  Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. , 1985, Nature.